Evidence map›Paper›PMID 40004200›Full record

ArticleInternational journal of molecular sciences2025

Investigating the Impact of NMDA Receptor Organization and Biological Sex in the APPswe/PS1dE9 Mouse Model of Alzheimer's Disease.

Senka Hadzibegovic, Bruno Bontempi, Olivier Nicole

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Neurotransmitter Systems in Alzheimer's Disease.Current issues in molecular biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Senka HadzibegovicNeurocentre Magendie, INSERM U1215, 33077 Bordeaux, France.ORCID 0000-0003-2333-8859
Bruno BontempiUniversity of Bordeaux, 33077 Bordeaux, France.
Olivier NicoleUniversity of Bordeaux, 33077 Bordeaux, France.ORCID 0000-0001-9981-1820

Funding

ANR MALZ ANR-10-MALZ-0001-02, project CorehAlz
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss and cognitive decline, with women being disproportionately affected in both prevalence and severity. A key feature of AD is synaptic loss, particularly around amyloid-β (Aβ) aggregates, which correlates strongly with the severity of dementia. Oligomeric Aβ is believed to be the primary driver of synaptic dysfunction by impairing excitatory neurotransmission through interactions with synaptic receptors, including N-methyl-D-aspartate (NMDA) receptors. However, the influence of sex on these synaptic changes and NMDA receptor mislocalization in AD is not well understood. This study examined potential sex-specific differences in synaptotoxicity and the role of extrasynaptic GluN2B-containing NMDA receptors in AD pathogenesis using the APP/PS1 double transgenic mouse model. Although both male and female mice showed a similar amyloid burden and cognitive impairments, synaptic alterations were slightly less severe in females, suggesting subtle sex differences in synaptic pathology. Both sexes exhibited the mislocalization of GluN2B subunits to extrasynaptic areas, which was linked to reduced PSD-95 levels and the synaptic accumulation of Aβ

Indexed as

Alzheimer DiseaseAmyloid beta-Protein PrecursorPresenilin-1Receptors, N-Methyl-D-AspartateAmyloid beta-PeptidesAnimalsDisease Models, AnimalDisks Large Homolog 4 ProteinFemaleHippocampusHumansMaleMiceMice, TransgenicSex CharacteristicsSex FactorsAmyloid beta-PeptidesAmyloid beta-Protein PrecursorDisks Large Homolog 4 ProteinNR2B NMDA receptorPresenilin-1Receptors, N-Methyl-D-AspartateextrasynapticmemoryNMDA receptorsPSD-95synaptotoxicity

Identifiers

PMID40004200
PMCPMC11855313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.